Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg

Published:2007-07-11 Issue:7 Volume:2 Page:e598
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Vedder Anouk C.,Linthorst Gabor E.,Houge Gunnar,Groener Johannna E.M.,Ormel Els E.,Bouma Berto J.,Aerts Johannes M.F.G.,Hirth Asle,Hollak Carla E.M.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference39 articles.

1. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.;RO Brady;N Engl J Med,1967

2. Fabry's disease: alpha-galactosidase deficiency.;JA Kint;Science,1970

3. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.;I Redonnet-Vernhet;J Med Genet,1996

4. α-Galactosidase A Deficiency: Fabry disease.;RJ Desnick,2001

5. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.;KD MacDermot;J Med Genet,2001

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease;Frontiers in Genetics;2024-04-12

2. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data;Drug Design, Development and Therapy;2024-04

3. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study;Orphanet Journal of Rare Diseases;2023-10-21

4. Right Ventricular Myocardial Involvement in Anderson–Fabry Disease at Diagnosis: Evaluation with Three-Dimensional Strain Imaging;Life;2023-07-16

5. Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review;Current Neuropharmacology;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3